Smartlab Europe

Lilly Announces New Vice President of Oncology Research

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

CMS Extends GENEROUS MFN Drug Pricing Deadline to April

The Centers for Medicare & Medicaid Services (CMS) in...

Lilly Launches New AI Supercomputer for Drug Development

Eli Lilly has launched what it describes as the...

Periodontal Disease as a Modifiable Risk Factor in Systemic Conditions

Periodontal disease has long been viewed primarily as a...
- Advertisement -

Eli Lilly and Company announced that Greg Plowman, M.D., Ph.D., will lead Lilly’s oncology research efforts as the vice president, oncology research and senior vice president of ImClone Systems research. In this innovative new role created by Lilly and ImClone, Plowman will oversee the oncology research efforts of both Lilly and its subsidiary, ImClone. Plowman will be based at ImClone’s research center at the Alexandria Center™ for Life Science — New York City and will start on March 28, 2011.

He will report jointly to Jan Lundberg, Ph.D., executive vice president, science and technology, and president, Lilly Research Laboratories (LRL), and Bernhard Ehmer, M.D., president of ImClone.

Latest stories

Related stories

CMS Extends GENEROUS MFN Drug Pricing Deadline to April

The Centers for Medicare & Medicaid Services (CMS) in...

Lilly Launches New AI Supercomputer for Drug Development

Eli Lilly has launched what it describes as the...

Periodontal Disease as a Modifiable Risk Factor in Systemic Conditions

Periodontal disease has long been viewed primarily as a...

How Pharma is Navigating EPR’s Split-Tier Reality in 2026 without Losing Regulatory Sterility

In 2026, the Pharmaceutical and Medical Device sectors face...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »